The 6 analysts offering 12-month price forecasts for Ovid Therapeutics Inc have a median target of 10.30, with a high estimate of 20.00 and a low estimate of 7.00. The median estimate represents a +76.37% increase from the last price of 5.84.
The current consensus among 7 polled investment analysts is to Buy stock in Ovid Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.35
Reporting Date Aug 06
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.